Intervacc AB (publ) (IVACC.ST)
SEK 2.38
(4.39%)
SEK 2.38
(4.39%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -93.57 Million SEK | -46.97% |
| 2022 | -64.41 Million SEK | -119.14% |
| 2021 | -29.39 Million SEK | -14.48% |
| 2020 | -25.67 Million SEK | 7.8% |
| 2019 | -27.84 Million SEK | 9.93% |
| 2018 | -30.91 Million SEK | -126.01% |
| 2017 | -13.68 Million SEK | -84.98% |
| 2016 | -7.39 Million SEK | -455.36% |
| 2015 | 2.08 Million SEK | -79.42% |
| 2014 | 10.11 Million SEK | 512.84% |
| 2013 | -2.44 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -18.78 Million SEK | -2.59% |
| 2024 Q1 | -17.81 Million SEK | 17.88% |
| 2023 Q1 | -17.44 Million SEK | 25.45% |
| 2023 Q3 | -36.93 Million SEK | -100.95% |
| 2023 Q4 | -21.69 Million SEK | 41.25% |
| 2023 FY | -94.67 Million SEK | -46.97% |
| 2023 Q2 | -18.38 Million SEK | -5.38% |
| 2022 FY | -64.41 Million SEK | -119.14% |
| 2022 Q2 | -15.73 Million SEK | -47.13% |
| 2022 Q1 | -10.69 Million SEK | -21.58% |
| 2022 Q4 | -23.39 Million SEK | -60.42% |
| 2022 Q3 | -14.58 Million SEK | 7.34% |
| 2021 Q2 | -6.14 Million SEK | 4.76% |
| 2021 Q4 | -8.79 Million SEK | -6.03% |
| 2021 FY | -29.39 Million SEK | -14.48% |
| 2021 Q1 | -6.45 Million SEK | 9.93% |
| 2021 Q3 | -8.29 Million SEK | -35.04% |
| 2020 Q3 | -6.4 Million SEK | -10.77% |
| 2020 FY | -25.67 Million SEK | 7.8% |
| 2020 Q2 | -5.78 Million SEK | 8.42% |
| 2020 Q4 | -7.16 Million SEK | -11.76% |
| 2020 Q1 | -6.31 Million SEK | 19.3% |
| 2019 Q4 | -7.82 Million SEK | -25.67% |
| 2019 Q2 | -8.43 Million SEK | -57.69% |
| 2019 Q1 | -5.35 Million SEK | 22.13% |
| 2019 FY | -27.84 Million SEK | 9.93% |
| 2019 Q3 | -6.23 Million SEK | 26.17% |
| 2018 Q2 | -12.3 Million SEK | -119.17% |
| 2018 FY | -30.91 Million SEK | -126.01% |
| 2018 Q4 | -6.87 Million SEK | -12.05% |
| 2018 Q3 | -6.13 Million SEK | 50.15% |
| 2018 Q1 | -5.61 Million SEK | 20.31% |
| 2017 Q4 | -7.04 Million SEK | -171.09% |
| 2017 Q2 | -1.98 Million SEK | 3.61% |
| 2017 FY | -13.68 Million SEK | -84.98% |
| 2017 Q1 | -2.05 Million SEK | 76.91% |
| 2017 Q3 | -2.59 Million SEK | -31.08% |
| 2016 Q2 | 563.85 Thousand SEK | 119.42% |
| 2016 Q4 | -8.9 Million SEK | -664.15% |
| 2016 FY | -7.39 Million SEK | -455.36% |
| 2016 Q3 | 1.57 Million SEK | 179.99% |
| 2016 Q1 | -2.9 Million SEK | 0.0% |
| 2015 FY | 2.08 Million SEK | -79.42% |
| 2014 FY | 10.11 Million SEK | 512.84% |
| 2013 FY | -2.44 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 62.416% |
| Ziccum AB (publ) | -21.56 Million SEK | -334.04% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -470.569% |
| BioArctic AB (publ) | 252.64 Million SEK | 137.04% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -10974.438% |
| Mendus AB (publ) | -100.65 Million SEK | 7.025% |
| Genovis AB (publ.) | 54.22 Million SEK | 272.579% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -503.268% |
| Active Biotech AB (publ) | -46.48 Million SEK | -101.314% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 619.624% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -68.863% |
| Aptahem AB (publ) | -10.1 Million SEK | -826.088% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 70.894% |
| Kancera AB (publ) | -65.04 Million SEK | -43.875% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 30.485% |
| Fluicell AB (publ) | -26.87 Million SEK | -248.149% |
| Saniona AB (publ) | -81.06 Million SEK | -15.437% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -656.438% |
| Biovica International AB (publ) | -126.07 Million SEK | 25.774% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -120.16% |
| AcouSort AB (publ) | -17.48 Million SEK | -435.135% |
| Xintela AB (publ) | -57.23 Million SEK | -63.491% |
| Abliva AB (publ) | -96.54 Million SEK | 3.075% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 71.189% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -2569.872% |
| OncoZenge AB (publ) | -15.9 Million SEK | -488.473% |
| Amniotics AB (publ) | -29.07 Million SEK | -221.876% |
| 2cureX AB (publ) | -36.36 Million SEK | -157.347% |
| CombiGene AB (publ) | -36.3 Million SEK | -157.757% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -539.201% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 75.656% |
| Camurus AB (publ) | 532.35 Million SEK | 117.578% |
| Corline Biomedical AB | -1.78 Million SEK | -5133.725% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 48.232% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -124.502% |
| I-Tech AB | 24.43 Million SEK | 482.971% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 88.132% |
| Cyxone AB (publ) | -21.66 Million SEK | -332.016% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 11.689% |
| Biosergen AB | -27.26 Million SEK | -243.22% |
| Cantargia AB (publ) | -290.01 Million SEK | 67.733% |
| NextCell Pharma AB | -43.17 Million SEK | -116.758% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 48.232% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -447.365% |
| Nanologica AB (publ) | -69.96 Million SEK | -33.755% |
| SynAct Pharma AB | -224.49 Million SEK | 58.316% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -111.832% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -290.657% |
| LIDDS AB (publ) | -40.67 Million SEK | -130.071% |
| Lipum AB (publ) | -37.25 Million SEK | -151.192% |
| BioInvent International AB (publ) | -369.94 Million SEK | 74.704% |
| Alzinova AB (publ) | -16.52 Million SEK | -466.39% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 63.077% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1363.716% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 18.679% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -364.666% |
| Simris Alg AB (publ) | -36.63 Million SEK | -155.436% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 36.153% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 69.855% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 15.629% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -709.087% |